Skip to main content
Back
Watch Compare

LakeShore Biopharma Co., Ltd.

Data quality: 100%
Also listed as LSBWF OTC
LSBCF
OTC Manufacturing Chemicals
$0.03
▼ $0.04 (-55.71%)
Mkt Cap: 2.88 M
Price
$0.07
Mkt Cap
2.88 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -18.62 M
Capital efficient — spends only 2.07% of revenue on capex

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)6.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-18.31%
Above sector avg (-54.01%)
ROIC-6.90%
Net Margin-16.26%
Op. Margin-14.03%

Safety

Debt / Equity
0.83
Above sector avg (0.30)
Current Ratio1.02
Interest Coverage-5.48

Valuation

PE (TTM)
-0.21
Above sector avg (-1.49)
P/B Ratio0.04
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1385 peers)
Metric Stock Sector Median
P/E -0.2 -1.5
P/B 0.0 1.6
ROE % -18.3 -54.0
Net Margin % -16.3 -41.5
Rev Growth 5Y % — 1.8
D/E 0.8 0.3

Analyst Price Target

No analyst coverage available

Earnings Estimates

No forward estimates available

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q12024 -$5.80 -$13.40 -131.0%
Q42023 -$4.20 -$8.30 -97.6%
Q32023 -$6.20 -$11.28 -82.0%
Q22023 N/A -$7.50 —

All Fundamental Metrics
Growth
Revenue Growth (1Y) 6.00% Revenue Growth (3Y) -7.44%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 85.67 M Net Income (TTM) -13.93 M
ROE -18.31% ROA -6.90%
Gross Margin 82.47% Operating Margin -14.03%
Net Margin -16.26% Free Cash Flow (TTM) -18.62 M
ROIC -6.90% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.83 Current Ratio 1.02
Interest Coverage -5.48 Asset Turnover 0.42
Working Capital 2.43 M Tangible Book Value 59.47 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.21 Forward P/E N/A
P/B Ratio 0.04 P/S Ratio 0.03
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -645.59%
Market Cap 2.88 M Enterprise Value 60.55 M
Per Share
EPS (Diluted TTM) -0.73 Revenue / Share 2.08
FCF / Share -0.45 OCF / Share -0.41
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 2.07% FCF Conversion 133.71%
SBC-Adj. FCF -20.51 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue 85.67 M 80.82 M 100.00 M
Net Income -13.93 M -61.09 M -21.17 M
EPS (Diluted) -0.73 -0.57 -0.23
Gross Profit 70.66 M 64.23 M 77.69 M
Operating Income -12.02 M -62.84 M -20.28 M
EBITDA — — —
R&D Expenses 20.39 M 42.68 M 46.38 M
SG&A Expenses — — —
D&A — — —
Interest Expense -2.19 M -6.25 M -4.49 M
Income Tax -131,910.0 -3.06 M 164,952.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 190.53 M 213.25 M 250.27 M
Total Liabilities 120.91 M 130.77 M 144.26 M
Shareholders' Equity 69.62 M 82.48 M 106.01 M
Total Debt 57.67 M 58.85 M 42.75 M
Cash & Equivalents — — 53.90 M
Current Assets 117.33 M 127.30 M 150.76 M
Current Liabilities 114.90 M 113.07 M 95.87 M